Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ELEVATE-45
ISRCTN18511908Phase 2Recruiting
- Sponsor
- Entrada Therapeutics
- Start
- Sep 2025
- Modality
- Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, MicroRNA (miRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Antisense Oligonucleotides (ASOs) → Long RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
01
Overview
Phase 2, randomised, double-blind trial in Duchenne muscular dystrophy (DMD) comparing ENTR-601-45 with ENTR-601-45 matching placebo (2 arms). Primary endpoint: Overall safety and tolerability of ENTR-601-45. Started Sep 2025; status: recruiting.
02
Drugs
ENTR-601-45
03
Conditions
Duchenne muscular dystrophy (DMD)
Beyond the preview
Go deeper on ISRCTN18511908.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ISRCTN18511908.